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Abstract
Background: For years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the
German population-based cancer registries and evaluating them together with the cause-of-death statistics
provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in
Germany on the basis of the available data from the regional cancer registries in which registration is complete;
this figure, in turn, forms the basis for further important indicators.
Methods: This article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival
rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of
cancer in Germany.
Results: According to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The
most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal
and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases
every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in
the current brochure on “Cancer in Germany”, which is regularly published by the RKI together with the
Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence
estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to
these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five
years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here,
too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of
developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than
among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops
cancer in the course of their lives. One in four men and one in five women die of cancer.
Conclusions: In recent years, population-based cancer registration in Germany has come significantly closer to the
aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help
describe cancer development in Germany.
Background
Since the Federal Cancer Surveillance Unit was founded
in 1983, first the Federal Health Office and then the
Robert Koch Institute (RKI) have been regularly pooling
and reviewing the data from the German population-
based cancer registries and evaluating them together
with the cause-of-death statistics provided by the statis-
tical offices. The Federal Cancer Registry Act, which
came into force in 1995, made it obligatory for all fed-
eral states (Länder) to set up population-based cancer
registries.
This law, which has expired in the meantime, gave the
development of cancer registration in the Länder a
major boost, with the result that a population-based
cancer registry now exists in every state. The federal act
also briefly described the tasks of the Federal Cancer
Surveillance Unit: i.e. to pool and evaluate the popula-
tion-based data from Germany’s cancer registries, and
to determine and regularly publish development trends
and regional differences. In addition, the law stipulated
that data from the regional population-based cancer
registries must be sent to the Robert Koch Institute
once a year. After the Act expired, this passage was
taken over in most of the Länder cancer registry laws
[1]. The last few federal states only recently laid the
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registration.
The Association of Population-based Cancer Registries
in Germany (GEKID) was formed in 2004. Its members
include not only the German population-based cancer
registries, but also a tumour centre and interested scien-
tists working in the field of cancer epidemiology. This
association’s primary task is to standardize as far as pos-
sible the content and methodology of cancer registra-
tion, despite the differences in legislation between the
Länder [2,3].
Since the usefulness of population-based data on the
incidence of cancer depends primarily on how comple-
tely all new cases of cancer are registered, the Federal
Cancer Surveillance Unit at the RKI regularly reviews
the completeness and reliability of the population-based
cancer registries in Germany. This level of quality has
been constantly improving in many Länder over the last
few years, with the result that the International Agency
for Research on Cancer (IARC) recently integrated
seven German cancer registries and their data into the
current edition of “Cancer in Five Continents” (Volume
IX). Traditionally, the RKI periodically estimates the
number of newly diagnosed cancer patients in Germany
on the basis of the data from regional population-based
cancer registries in which registration is complete; in
turn, these figures form the basis for other important
indicators such as prevalence rates and cancer-risk
estimates.
This article gives a brief overview of current indicators
- such as incidence, prevalence, mortality, survival rates
- on the most common types of cancer, as well as
important ratios on the risks of developing and dying of
cancer (morbidity and mortality risks) in Germany.
Detailed information on incidence, mortality and survi-
val rates for more cancer sites is available in the latest
brochure on “Cancer in Germany” (6th edition 2008),
which is published jointly every two years by the RKI
and GEKID [2].
Methods
Data sources
The basis for the RKI’s periodic estimate of the number
of new cancer cases occurring in Germany is provided
by the morbidity data from the German population-
based cancer registries in which registration is complete,
as well as regional and federal mortality data.
The current estimate is based on the epidemiological
case records of the population-based cancer registries in
Germany up to 2004, which the RKI receives every year
in anonymized form. International and national experi-
ence has shown that it takes more than two years before
the population-based cancer registries’ records on many
cancer types are virtually complete; this is how long it
takes before subsequent data collection and all compari-
sons with the existing registry data and death certificates
have been essentially completed. The national mortality
data from the statistical offices are currently available up
to 2006. Because of the need for comparability with the
registry data, this article also only processes mortality
data up to 2004.
The annually updated figures on the average popula-
tion provided by the statistical offices are used as the
reference variable for the cancer morbidity and mortality
data and thus cover all people who are resident in Ger-
many, regardless of their nationality. As part of its 11th
coordinated population projection, Germany’s Federal
Statistical Office offers several variations of cutoff-date-
related population data broken down by age and sex for
the years from 2006 to 2050 [4]. The individual varia-
tions reflect different assumptions on the future devel-
opment of fertility, life expectancy and immigration.
The present article is based on the 1 W-1 version,
which makes moderate assumptions on each of the
three factors mentioned above.
Recoding between the ICD-9, ICD-10 and ICD-O clas-
sifications was necessary in some cases. This was done
using a conversion tool issued by DIMDI (German Insti-
tute for Medical Documentation and Information) and
the so-called “IARCcrgTools” provided by the Interna-
tional Agency for Research on Cancer (IARC), based in
Lyon, France [5,6]. This program was also used to apply
the definitions recommended by the IARC on the inde-
pendence of different primary tumours in a single per-
son, to ensure that cancer incidence is correctly
calculated.
Statistical analysis
The completeness of the population-based data from the
German cancer registries analysed every year by the RKI
is checked using a procedure that has been agreed with
t h er e g i s t r i e s[ 7 ] .A ss t a t e di nt h eb r o c h u r e“Cancer in
Germany” [2], in addition to the cancer registries that
have been established for many years there are also
numerous more recently formed registries. In the Saar-
land, cancer cases have been recorded with a high
degree of continuity and stability for over 40 years, so
that these data meet international standards of quality
and completeness. To check the completeness of the
other German cancer registries, the RKI first estimates
incidence in the relevant catchment area on the basis of
data from the Saarland’s cancer registry (reference
region) and compares this figure with the data actually
collected by the respective registry. The ratios of inci-
dence and mortality in the reference region are used for
each site and gender to estimate cancer incidence levels,
taking into account mortality in the region studied. The
incidence rates are fitted using a Poisson regression
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the independent variable [8]. The IARC also uses Pois-
son regression models with mortality as the offset in the
context of the GloboCan programme to estimate world-
wide cancer incidence, albeit with age and sex as inde-
pendent variables [9]. Where the level of completeness
of the examined cancer registry is found to be adequate,
the data acquired in this way are added to a data pool
for a new reference region. In a second step, every regis-
t r yi sa g a i nc h e c k e da g a i n s tt h ed a t ap o o li no r d e rt o
determine level of completeness. As mentioned above,
the latest results of the completeness estimate, which
are broken down by sex, cancer site, age and region, are
available in the current brochure on “Cancer in Ger-
many” [2]. The newly created data pool also forms the
basis for the nationwide estimate of the number of new
cancer cases. As in the regional incidence estimate, the
observed number of new cancer cases in the data pool
is projected to the national level, taking national mortal-
ity into account [10].
Not only the past, but also the future development of
new cancer cases is of major importance for public
health policy. It provides clues on the likely level of
pressure on the health system. In order to judge the
possible effects of demographic developments on the
incidence of cancer in Germany, this article simplifies
the situation by assuming that the estimated current
age-specific cancer incidence rates will not change in
the coming years. This makes it possible to focus on
quantifying the consequences of the changes in the
future population structure that are expected according
to the Federal Statistical Office’sc u r r e n tp o p u l a t i o n
projections.
In addition to the two basic indicators (incidence
and mortality) used to describe the development of the
disease at the population level, prevalence is of parti-
cular interest for research into healthcare provision to
assess the demand for care facilities and to plan for
requirements accordingly. Prevalence is defined as the
total number of people in the resident population who
currently have cancer - or have had the disease in the
p a s t .T h i sf i g u r et h u se s t i m a t e st h en u m b e ro fp e o p l e
in a population who are using certain care facilities at
the same time. The problem with this indicator is
deciding on the date when the patients are considered
cured, because a cancer patient can suffer a relapse
even after many years without symptoms. Furthermore,
different cancer patients use the various care facilities
to varying degrees in the course of the disease. Data
on the total number of people still living who have
had cancer at some time in the past, or still have the
disease today, is certainly of less practical importance
for care research. This article, therefore, does not pre-
sent overall figures on all prevalent cases, but what are
known as partial prevalence. These describe the num-
ber of patients still living who had cancer no more
than 1, 2, 3, 4 or 5 years ago. The method used to cal-
culate the indicators is based on the IARC’sa p p r o a c h
in the context of the Globocan programme [9,11]. In
addition to the number of new cases in past years, the
calculation method requires detailed information on
the survival expectations of patients with the respective
cancer. The IARC does not estimate the required
observed survival rates themselves, but calculates them
indirectly from available relative survival rates. The
RKI used period analyses to calculate the observed sur-
vival rates in Germany directly from data from the
Saarland Cancer Registry [12]. Furthermore, relative
survival rates are presented for the current period win-
dow (2000-2004) according to Hakulinen’sm e t h o d
[13], using national German life tables. Like the
EUROCARE-4 study [14], the RKI also age-standar-
dized the relative survival rates to enable comparisons
to be made with the results of this international study.
T h ec a l c u l a t i o nw a sm a d ew i t haS t a t ap r o g r a mf r o m
Dickman et al. [15]. Moreover, as in the EUROCARE-4
study, the relative survival rates of patients with differ-
ent cancers were age-standardized using different stan-
dards [16].
In addition to the indicators mentioned above, which
are of particular interest for administrative planning,
this article also presents indicators on cancer-morbidity
and cancer-mortality risk, which are easier to relate to
individuals. In this context, the age-conditional risk
describes the probability of a person of a given age
developing or dying of cancer within a specified number
of years. The lifetime risk is a special case of age-condi-
tional risk and relates to the probability of a newborn
child developing or dying of cancer within the course of
his or her life. The method of calculating the indicators
follows the approach of Fay et al. [17] and uses the Dev-
Can program [18] of the National Cancer Institute of
the USA
Results
Estimated incidence and mortality
Figure 1 shows long-term trends of the estimated age-
standardized incidence rates for the three most common
cancers in men and women for the period between 1980
and 2004 in Germany.
According to the RKI’s current estimate, prostate can-
cer incidence showed the highest increase throughout
the entire observation period. Prostate cancer, with cur-
rently about 58,000 new cases per annum, is now the
most common cancer in men, followed by colorectal
cancer (see Table 1). The incidence of lung cancer,
which used to be the most common malignant neo-
plasm in men, has been declining markedly since the
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ectal cancer.
In women, breast cancer remains the most common
form of cancer with over 57,000 new cases in 2004, fol-
lowed by colorectal cancer with about 36,000 cases.
What is remarkable is the sharp increase in the rates of
lung cancer among women, a trend that can also be
observed in other European countries. According to the
current estimate, the total percentage increase in the
lung cancer incidence rate among women is 150% com-
pared to 1980.
This means that, between 1980 to 2004, the age-stan-
dardized incidence rates for breast cancer rose to 150%
and for prostate cancer to 250% of the respective figure
for 1980 (see Figure 1). When the impact of demo-
graphic change is not offset by age standardization, the
annual number of new cases of prostate cancer rises to
as much as 340%, and for breast cancer to 170% of its
initial value (see Figure 2).
Table 1 Estimated number of new cancer cases and observed number of cancer deaths in Germany in 2004 (in
brackets: age-standardized rates related to European population/2000 U.S. standard population).
Site (ICD-10) Male Female
New Cases
(Incidence rates)
Deaths
(Mortality rates)
New Cases
(Incidence rates)
Deaths
(Mortality rates)
Colorectal (C18-C21) 37,254
(72.6/78.0)
13,748
(26.9/31.4)
36,004
(49.3/55.1)
14,034
(17.0/20.7)
Lung (C33, C34) 32,848
(64.4/67.3)
28,820
(55.9/60.0)
13,188
(21.8/21.8)
11,026
(17.0/17.7)
Breast (C50) 57,231
(104.2/102.2)
17,592
(26.8/28.4)
Prostate (C61) 58,574
(112.0/117.7)
11,135
(22.2/29.6)
All cancer sites
(C00-C97 except C44)
230,464
(453.6/480.3)
110,745
(218.7/248.7)
206,010
(330.8/344.1)
98,079
(135.2/151.7)
Figure 1 Development of estimated age-standardized
incidence rates (European population) of the most common
cancer sites in men and women in Germany.
Figure 2 Development of the estimated and extrapolated
number of new cases of the most common cancer sites in men
and women in Germany up to 2020.
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new cancer cases in Germany at about 436,500 for 2004:
230,500 among men and 206,000 among women. This
means an increase of more than 60% over 1980. Figure
3 shows the development of the age-standardized mor-
tality rates of selected cancer sites. Only lung cancer
mortality among women shows a sharp increase.
Figure 2 shows both the past development of new
cancer cases and the extrapolated case figures up to
2020. In addition, Table 2 lists the corresponding age-
specific new cases. On the simplifying assumption that
the estimated current cancer incidence rates will remain
constant in the future, the number of new cancer cases
for all the sites observed here will rise sharply to a total
of approximately 530,000 cases in 2020 - solely as a
result of the anticipated demographic changes. Only in
t h eu n d e r - 4 5a g eg r o u pw i l lt h ef u t u r en u m b e ro fn e w
cases for all cancer sites decline, since the Federal Statis-
Figure 3 Development of the age-standardized mortality rates
(European population) of the most common cancer sites in
men and women in Germany.
Table 2 Extrapolated number of new cancer cases in
Germany up until 2020.
Year
Site (ICD-10) Age group 2010 2015 2020
Male
Colorectal (C18-C21) 0-44 860 712 688
45-64 11,228 12,631 13,496
65-84 27,750 29,063 30,634
85+ 2,490 3,423 4,189
All ages 42,328 45,829 49,007
Lung (C33, C34) 0-44 548 440 426
45-64 11,425 12,782 13,552
65-84 23,628 24,654 25,757
85+ 1,436 1,863 2,212
All ages 37,037 39,739 41,947
Prostate (C61) 0-44 0 0 0
45-64 16,604 18,928 20,805
65-84 45,974 47,542 49,823
85+ 3,257 4,434 5,406
All ages 65,835 70,904 76,034
All cancer sites
(C00-C97 except C44)
0-44 11,019 9,736 9,406
45-64 72,186 80,825 85,547
65-84 163,502 171,026 179,207
85+ 12,108 16,321 19,780
All ages 258,815 277,908 293,940
Female
Colorectal (C18-C21) 0-44 816 699 681
45-64 7,627 8,488 8,799
65-84 23,736 24,589 25,936
85+ 6,463 7,184 7,624
All ages 38,642 40,960 43,040
Lung (C33, C34) 0-44 504 410 397
45-64 5,096 5,610 5,762
65-84 7,423 7,529 7,804
85+ 969 1,066 1,125
All ages 13,992 14,615 15,088
Breast (C50) 0-44 5,678 4,763 4,632
45-64 27,317 29,800 29,960
65-84 23,696 23,744 24,929
85+ 3,170 3,512 3,718
All ages 59,861 61,819 63,239
All cancer sites
(C00-C97 except C44)
0-44 15,646 13,597 13,174
45-64 66,973 73,654 75,050
65-84 109,926 112,281 117,904
85+ 25,098 27,762 29,391
All ages 217,643 227,294 235,519
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population projections up to 2020.
Survival rates
Figure 4 shows the development of the cumulative rela-
tive survival rates of people suffering from the cancers
covered in this article over the first 10 years after diag-
nosis. Of these sites, the survival expectations of male
patients diagnosed with prostate cancer are the most
favourable, followed by female patients with breast can-
cer. The survival expectations of patients with lung can-
cer are still very unfavourable for both sexes [19]. A
comparison of the current 5-year relative survival rates
calculated here using period analysis (period window
2000-2004) with the results of a traditional cohort analy-
sis (diagnosis period 1993-1997) shows particularly strik-
ing improvements in the case of prostate cancer within
this short time span [1].
Table 3 shows both the cumulative 5-year observed
survival rates and the corresponding cumulative 5-year
relative survival rates with and without age standardiza-
tion. Age standardization facilitates international com-
parisons, for example with the results of the current
EUROCARE-4 study, the results of which are based on
the same age standards, or with the results of the CON-
CORD study of colorectal, breast and prostate cancer,
which relate to the 1990-1994 diagnosis interval and
include not only participating European countries, but
also countries on all continents, for example the USA
and Canada [14,20].
Figure 4 Cumulated relative survival rates for selected cancer
sites.
Table 3 Observed, relative and age-standardized relative
5-year survival rates (as %) including the 95% confidence
intervals for the 2000-2004 period.
Site
(ICD-10)
5-year survival rates
observed relative age-stand. relative
Male
Colorectal (C18-C21) 49.2
47.2 - 51.0
60.4
58.1 - 62.7
60.1
54.6 - 65.3
Lung (C33, C34) 13.0
11.8 - 14.2
15.5
14.1 - 17.0
15.4
12.1 - 19.2
Prostate (C61) 69.8
68.3 - 71.4
87.3
85.3 - 89.2
86.0
80.5 - 90.9
All cancer sites
(C00-C97 except C44)
43.8
43.0 - 44.6
52.8
51.8 - 53.7
52.2
50.1 - 54.2
Female
Colorectal (C18-C21) 48.1
46.2 - 50.0
60.0
57.6 - 62.4
61.8
56.4 - 66.6
Lung (C33, C34) 15.8
13.6 - 18.2
17.8
15.3 - 20.5
16.6
11.8 - 22.5
Breast (C50) 72.5
71.2 - 73.8
81.1
79.6 - 82.5
79.6
76.1 - 82.8
All cancer sites
(C00-C97 except C44)
51.3
50.5 - 52.1
59.9
59.0 - 60.9
58.3
56.4 - 60.2
Table 4 Number of cancer cases in 2004 in Germany
diagnosed over the last × years (percentages related to
German population on cutoff date 31 Dec. 2004).
Site
(ICD-10)
Number of cancer cases diagnosed over the
last
1 year 3 years 5 years
Male
Colorectal (C18-C21) 32,400(0.08%) 79,350(0.20%) 114,509(0.28%)
Lung (C33, C34) 20,847(0.05%) 34,162(0.08%) 42,242(0.10%)
Prostate (C61) 56,025(0.14%) 149,497(0.37%) 222,254(0.55%)
All cancer sites
(C00-C97 except C44)
202,261(0.50%) 456,087(1.13%) 644,302(1.60%)
Female
Colorectal (C18-C21) 31,131(0.07%) 76,988(0.18%) 113,208(0.27%)
Lung (C33, C34) 8,750(0.02%) 15,009(0.04%) 18,623(0.04%)
Breast (C50) 55,043(0.13%) 152,768(0.36%) 235,779(0.56%)
All cancer sites
(C00-C97 except C44)
189,488(0.45%) 460,509(1.09%) 678,955(1.61%)
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Table 4 shows the number of cancer cases by sex and
site that occurred in Germany in 2004 and the previous
years. A distinction was made between 1-, 3- and 5-year
partial prevalence estimates. The corresponding percen-
tages of the total population are given in brackets.
According to these figures, in 2004 there were over 1.3
million people living in Germany who had had cancer
during the 5 years between 2000 and 2004 (5-year par-
tial prevalence), with a slightly higher proportion of
women than men. Over one third of all prevalent cases
in men were prostate cancer that had occurred no more
than 5 years previously; in women, a third of the cases
were breast cancer. The 5-year partial prevalence of col-
orectal cancer was virtually identical in men and women
at about 110,000 cases respectively; incidence rates and
survival rates were similar in both sexes. It may be sur-
prising that the 1-year partial prevalence estimates were
lower than the corresponding cancer incidence figures -
not only in the case of colorectal cancer. However,
while incidence indicates the total number of all cases
of cancers that occurred between 1 January and 31
December each year, prevalence shows how many peo-
ple had cancer on a certain date in the year - the cutoff
date. Since not all patients survive the first year after
diagnosis, the 1-year partial prevalence must always be
lower than the respective incidence.
Cancer risk
As Table 5 shows, approximately every second person in
Germany develops cancer in the course of their life,
although this roughly rounded result conceals the fact
that the lifetime risk is higher for men than for women.
On the other hand, only one in four men and one in
every five women die of cancer (see Table 6).
The highest cancer risk for men is prostate cancer, for
women breast cancer. In the case of breast cancer, the
risk is highest among middle-aged people, unlike the
Table 5 Probability of developing cancer within selected age intervals, by sex and selected sites, Germany.
Age-conditional morbidity risk
Site (ICD-10) Birth to 49 50 to 69 70 and older Lifetime morbidity risk
Male
Colorectal (C18-C21) 0.3% 3.3% 6.5% 8.0%
Lung (C33, C34) 0.3% 3.1% 5.1% 6.9%
Prostate (C61) 0.1% 5.5% 10.2% 12.4%
All cancer sites
(C00-C97 except C44)
3.3%(1 in 31) 20.4%(1 in 5) 42.9% (1 in 2) 48.5%(1 in 2)
Female
Colorectal (C18-C21) 0.3% 2.1% 5.9% 7.3%
Lung (C33, C34) 0.2% 1.1% 1.4% 2.5%
Breast (C50) 2.0% 5.3% 4.5% 10.7%
All cancer sites
(C00-C97 except C44)
4.8%(1 in 21) 15.5%(1 in 6) 28.5% (1 in 4) 40.3%(1 in 2)
Table 6 Probability of dying of cancer within selected age intervals, by sex and selected sites, Germany.
Age-conditional mortality risk
Site (ICD-10) Birth to 49 50 to 69 70 and older Lifetime mortality risk
Male
Colorectal (C18-C21) 0.1% 1.0% 3.1% 3.3%
Lung (C33, C34) 0.2% 2.5% 4.9% 6.2%
Prostate (C61) 0.0% 0.5% 3.8% 3.2%
All cancer sites
(C00-C97 except C44)
1.0%(1 in 103) 8.3%(1 in 12) 22.9% (1 in 4) 25.7%(1 in 4)
Female
Colorectal (C18-C21) 0.1% 0.5% 2.8% 3.0%
Lung (C33, C34) 0.1% 0.8% 1.4% 2.2%
Breast (C50) 0.3% 1.2% 2.4% 3.5%
All cancer sites
(C00-C97 except C44)
1.0%(1 in 97) 5.4%(1 in 18) 16.2% (1 in 6) 20.2%(1 in 5)
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with the disease rises in old age. Compared to the last,
corresponding RKI estimates for 2000, a 50-year-old
woman’s risk of developing breast cancer by her 70th
year has now risen by one percentage point to 5.3% [1].
In men, the risk of being diagnosed with prostate cancer
at this time of life has increased from 3.5% to currently
5 . 5 % .O v e r a l l ,t h el i f e t i m er i sk of developing the latter
disease has risen since 2000 by about 3% to currently
12.4%.
Discussion
The RKI’s annual assessment of the completeness of the
German cancer registry data shows that the coverage
levels vary considerably from one cancer site to another.
The data on a certain site from cancer registries deemed
to be complete are merged and form the basis of the
national estimates on cancer incidence. Coverage of
breast cancer is the most complete of all the cancers
studied here in all the registries. Concerning this cancer
site the catchment areas of the participating cancer
registries currently already cover 25% of the female
population in Germany. Coverage of colorectal cancer,
by contrast, is much worse: here, only 1.3% of the total
population live in the catchment areas of the participat-
ing registries. The estimate on new cases of breast can-
cer is therefore based on a much more stable data
foundation than other cancer sites.
Smoking has been recognized as a major risk factor
for lung cancer for a long time. Levels of lung-cancer
incidence and mortality largely reflect the population’s
past cigarette consumption. While tobacco consumption
in Germany has decreased slightly among men since the
mid-1980s, it is increasing among women. As a result,
the smoking behaviour of the two sexes is increasingly
converging [21], as reflected in decreasing lung-cancer
incidence and mortality rates among men and rising
rates among women.
The population’s increased participation in screening
tests is certainly one reason for the sharp increase in
new cancer cases. A major factor in the case of men is
blood testing for prostate-specific antigen (PSA), com-
bined with earlier diagnosis [2,22,23]. The currently
ongoing nationwide introduction of mammography
screening for women has attracted considerable public
attention and prompted several pilot projects in differ-
ent regions of Germany in recent years. These have con-
tributed to the sharp estimated increase in the number
of new cases of breast cancer, although the most recent
estimates indicate that the increase is no longer as steep
as it has been in the past. Demographic changes
(changes in the age structure) are another important
cause of the increase. The extrapolations on the future
development of cancer in Germany up to 2020 show
that, even if cancer rates remain unchanged, the number
of new cancer cases will grow significantly over the next
few years, especially among men, solely as a result of
the growing proportion of elderly people in the popula-
tion that is anticipated in the future. However, a further
s t u d yb yt h eR K Ia l s os h o w st h a tt h en u m b e ro fd e a t h s
from cancer could even fall in the following years,
despite the above-mentionedd e m o g r a p h i cc h a n g e s ,i f
the trend towards declining mortality rates for all cancer
sites that has been observed since the 1990s continues
[24].
The survival expectations of men and women with the
same cancer site differ only slightly overall, as shown by
the overlapping 95% confidence intervals in the cumula-
tive 5-year relative survival rates in Table 3. Overall, the
significantly better survival rates for women with cancer
are essentially based on gender-specific differences in
the range of cancer sites - lung cancer being more com-
mon in men and breast cancer in women. The age-stan-
dardized survival rates shown in Table 3 are all above
the respective average European figures given in the
EUROCARE-4 study [14]. By contrast, with the excep-
tion of lung cancer, the North American SEER pro-
gramme indicates much higher survival rates than the
current rates calculated here [25]. If the same age stan-
dard as in the EUROCARE-4 study is used, as in the
case of the CONCORD study, as early as the diagnosis
years 1990-1994 this leads to only slightly less favour-
able results for colorectal cancer in the USA and
Canada compared to the survival rates calculated by the
RKI. In the case of breast cancer in women, the survival
rates in the early 1990s in the USA and Canada are
a l r e a d ys l i g h t l yh i g h e rt h ecurrent survival rate in Ger-
many. The prostate-cancer survival rates in North
America were already significantly better among patients
diagnosed in the early 1990s; within Europe they were
only comparable with the results from the Austrian
state of Tyrol. The survival rates in Germany for the
diagnosis years 2000-2004 presented in this paper corre-
spond to those previously calculated for Canada and
Austria [20].
Life expectancy in the Saarland is currently below the
national average in both men and women [21]. Since
the observed survival rates are currently still based
exclusively on the survival experience of Saarland cancer
patients, and since the rates are calculated taking into
account all deaths, including deaths not caused by can-
cer, the reported survival rates probably slightly under-
estimate survival prospects of German cancer patients
nationwide, with corresponding effects on the preva-
lence estimates.
The high morbidity risks, especially the lifetime risks -
particularly in the case of prostate cancer in men and
breast cancer in women as shown in Table 5 - must be
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measures and therefore interpreted cautiously. It seems
that it is not the risk of developing cancer that has
increased, but the likelihood that such a disease will be
detected and diagnosed at a younger age and an earlier
stage of the disease. In both sites the increase in the
morbidity risks is accompanied by a slight decline in
mortality risks.
In general, when interpreting the above-mentioned
morbidity and mortality risks, it should be borne in
mind that the estimates made are based on the experi-
ence of the general population, and the only individual
characteristics that are taken into account are gender
and age. The morbidity and mortality risk of each indi-
vidual can be higher or lower, depending on their perso-
nal behaviour, genetic predisposition and exposure to
exogenous factors.
Conclusions
In recent years, population-based cancer registration in
Germany has come significantly closer to the aim of the
complete, nationwide coverage of cancer. On the one
hand, the data currently available in Germany help
describe cancer development in the past; on the other,
they provide the data for other predictions on possible
developments in the field of cancer in Germany. In this
context population-based survival rates represent an
important indicator for evaluating the effectiveness of
healthcare services. Estimates on the number of new can-
cer cases to be expected in the future are also an impor-
tant aspect for requirements planning in healthcare. The
continuous improvements in the data situation over the
past few years make it possible, using simplifying
assumptions, to indicate possible developments of cancer
incidence in Germany up until 2020, both for cancer as a
whole and for individual cancer sites. These can then be
used to assess the effectiveness of certain public-health
measures (e.g. screening programmes) in the fight against
cancer and, where appropriate, to uncover areas where
things are going wrong - in the interest of the individuals
affected by a cancer diagnosis.
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